Kenneth Todd Moore (Jinshan Shen, Kenneth T Moore)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 21

Top Venues

Journal of clinical pharmacology

Current medical research and opinion

Current hypertension reports

Journal of thrombosis and thrombolysis

Janssen Pharmaceuticals

Fairleigh Dickinson University College at Florham (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Janssen Pharmaceuticals Dec 16 2006

United States

Scientific Director :: Medical Affairs

Bristol Myers Squibb Co

United States

Clinical Scientist :: Clinical Pharmacology

Education History

Fairleigh Dickinson University College at Florham Sep 01 1998 - Jun 01 2003

United States

MSC :: Biology

Publications

Kenneth Todd Moore, Aman Gupta, Jinshan Shen, Parag Kumar
Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists. Journal of clinical pharmacology (2024)
John Mark Flack, Michael Gregory Buhnerkempe, Kenneth Todd Moore
Resistant Hypertension: Disease Burden and Emerging Treatment Options. Current hypertension reports (2024)
John Mark Flack, Michael Gregory Buhnerkempe, Kenneth Todd Moore
Resistant Hypertension: Disease Burden and Emerging Treatment Options. Current hypertension reports 26 (5) (2024)
John Mark Flack, Michael Gregory Buhnerkempe, Kenneth Todd Moore
Resistant Hypertension: Disease Burden and Emerging Treatment Options. Current hypertension reports 26 (5) (2024)
Kenneth Todd Moore, Kenneth T Moore, Suneet Shukla, Karen Yeo, Karthik Venkatakrishnan, null null
Inclusion of obese participants in drug development: Reflections on the current landscape and a call for action. Journal of clinical pharmacology (2023)
Kenneth Todd Moore, Peter N Zannikos, Joanna C Masters, Stefan Willmann, Jinshan Shen, Charles Frost
The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development. Journal of clinical pharmacology (2023)
Jeffrey S Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre, Veronica Ashton
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States. Journal of thrombosis and thrombolysis 54 (3) (2022)
Kenneth Todd Moore, Oliver Grundmann, Otito Iwuchukwu, Natella Rakhmanina, null null
The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct. Journal of clinical pharmacology 62 (12) (2022)
Kenneth Todd Moore, Michael J Fossler, Islam R Younis, null null
The Importance of Participant Tracking When Conducting Clinical Pharmacology Drug Trials. Journal of clinical pharmacology 62 (12) (2022)
Kenneth Todd Moore, Sudhakar M Pai, Mark Rogge, null null
Drug Lawsuit Advertisements and the Importance of Physician Consultation Prior to Voluntary Medication Withdrawal or Transition. Journal of clinical pharmacology 62 (12) (2022)
Jeffrey S Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre, Veronica Ashton
Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population. Journal of medical economics 24 (1) (2021)
Jeffrey S Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre, Veronica Ashton
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. Current medical research and opinion 37 (6) (2021)
Veronica Ashton, Lana Mudarris, Kenneth Todd Moore
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. American journal of cardiovascular drugs : drugs, devices, and other interventions 21 (3) (2021)
François Laliberté, Veronica Ashton, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre, Jeffrey S Berger
Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. Journal of comparative effectiveness research 10 (16) (2021)
Veronica Ashton, Sylvia Kerolus-Georgi, Kenneth Todd Moore
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations. Journal of clinical pharmacology 61 (8) (2021)
Jeffrey S Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre, Veronica Ashton
Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US). Advances in therapy 38 (7) (2021)
Alok A Khorana, John Barnard, Ted Wun, Ujjwala Vijapurkar, C V Damaraju, Kenneth Todd Moore, Peter Wildgoose, Keith R McCrae
Biomarker Signatures in Cancer Patients With and Without Venous Thromboembolism Events: A Substudy of CASSINI. Blood advances (2021)
Olivia S Costa, Jan Beyer-Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J Bunz, Craig I Coleman
Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Current medical research and opinion 36 (7) (2020)
Kenneth Todd Moore
Clarification-safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis. Pacing and clinical electrophysiology : PACE 41 (7) (2018)
Kenneth Todd Moore, Peggy Wong, Liping Zhang, Guohua Pan, JoAnne Foody
Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban. Current medical research and opinion 34 (12) (2018)
Kenneth Todd Moore
Clarification of the use of rivaroxaban in renal patients. British journal of haematology 185 (2) (2018)

Kenneth Todd Moore.css-eqlu8i{font-size:small;padding-left:4px;} (Jinshan Shen, Kenneth T Moore)

Publication Activity (10 Years)

Top Topics

Top Venues

Kenneth Todd Moore (Jinshan Shen, Kenneth T Moore)